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Estrogens have well-documented effects on lung development and physiology. However, the classical estrogen
receptor  (ER) is undetectable in the lung, and this has left many unanswered questions about the
mechanism of estrogen action in this organ. Here we show, both in vivo and in vitro, that ER is abundantly
expressed and biologically active in the lung. Comparisons of lungs from wild-type mice and mice with an
inactivated ER gene (ER/) revealed decreased numbers of alveoli in adult female ER/ mice and
findings suggesting deficient alveolar formation as well as evidence of surfactant accumulation. Platelet-
derived growth factor A (PDGF-A) and granulocyte-macrophage colony-stimulating factor (GM-CSF), key
regulators of alveolar formation and surfactant homeostasis, respectively, were decreased in lungs of adult
female ER/ mice, and direct transcriptional regulation of these genes by ER was demonstrated. This
suggests that estrogens act via ER in the lung to modify PDGF-A and GM-CSF expression. These results
provide a potential molecular mechanism for the gender differences in alveolar structure observed in the adult
lung and establish ER as a previously unknown regulator of postnatal lung development and homeostasis.
The vital function of the lung is to provide a gas-exchange
surface to meet the organism’s needs for oxygen uptake and
carbon dioxide elimination. Several parameters in lung biology
and pathology, both during development and in the adult, are
sexually dimorphic. A role for estrogen in these dimorphisms
was suggested in 1980 when Mendelson et al. (21) showed an
estrogen-binding component in human fetal lung tissue. Lung
maturation during fetal development is more rapid in female
fetuses than in male fetuses, and the onset of surfactant syn-
thesis occurs later in the male fetus. This difference appears to
be mediated mainly by inhibitory effects of androgens, but
stimulatory effects of estrogens have also been demonstrated
(2). Postnatal sex differences in the rodent lung have been
described by Massaro et al. (20). Adult females have a larger
number of alveoli, smaller in size, than males, probably to
allow for elevated oxygen consumption during pregnancy and
lactation. This difference develops as animals reach sexual ma-
turity and seems to be mediated mainly by estrogens (19). In
the human population, women are more prone than men to
developing chronic obstructive pulmonary disease (29) and
incur a higher risk of developing lung cancer (13, 41), indicat-
ing that women are more susceptible to the deleterious effects
of tobacco smoking. The reasons for these sex differences are
unknown, but estrogens are likely to play a major role, since in
animal models, there are estrogen-dependent gender differ-
ences in susceptibility towards tobacco-associated lung carcin-
ogens (23), and furthermore, epidemiological studies suggest
that hormone replacement therapy with estrogen is associated
with a higher risk of lung cancer in postmenopausal women (1,
39).
Although previous data suggest that estrogens might be im-
portant in lung development, physiology, and carcinogenesis,
there is very little information about estrogen receptor-depen-
dent functions in the lung. This is most likely related to the
absence of estrogen receptor alpha (ER) in this tissue, which,
for many years, was considered to be the only estrogen recep-
tor. To better understand the role of estrogen in the lung, we
have investigated the expression and physiological role of ER
(16) in the lung. In this paper, we show that ER is abundantly
expressed and biologically active in the lung. Comparisons of
lungs from wild-type (WT) and ER/ female mice indicate
that this receptor modulates alveolar structure and surfactant
homeostasis. Analysis of gene expression in WT and ER/
female mice and studies of transcriptional regulation show that
platelet-derived growth factor A (PDGF-A), which plays a
pivotal role in alveolar formation (4, 18), and granulocyte-
macrophage colony-stimulating factor (GM-CSF), a key regu-
lator of surfactant homeostasis (9, 38), are both controlled at
the transcriptional level by estrogens via ER in the lung. This
provides a mechanism for the modulation of alveolar structure
and surfactant homeostasis by estrogen.
MATERIALS AND METHODS
Animals. The generation of ER knockout and estrogen response element
(ERE) reporter mice has been described elsewhere (7, 14). All other mice were
C57BL/6.
Fixation and tissue preparation. Animals were killed through cervical dislo-
cation, and anterior chest walls were removed. A cannula was inserted into the
trachea and tied firmly in place. The trachea and lungs were infused with 4%
paraformaldehyde (pH 7.4) at 20 cm H2O pressure and maintained at this
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pressure for 5 min or removed without intratracheal infusion. The lungs were
subsequently kept in fixative overnight at 4°C. After fixation, the lungs were
dehydrated through a graded series of ethanol. Finally, the right and left lungs
were separated and placed into individual cassettes and embedded in paraffin.
The central portions of the blocks were sectioned at 5-m intervals, and the
sections were mounted on glass slides, deparaffinized, and hydrated for staining.
Immunohistochemistry and immunofluorescence. The cellular presence of
ER and  was detected by standard immunohistochemistry procedures as
described by Patrone et al. (26) with some modifications. Briefly, for detection of
ER, the rabbit polyclonal antibody MC20 from Santa Cruz Biotechnology
(Santa Cruz, Calif.) was used, and for ER, the chicken polyclonal ER 503
immunoglobulin Y (33, 40), made by immunization with ER 503, was used.
ER 503 is human ER1, modified in its ligand-binding domain (LBD) by
insertion of the rat 18-amino-acid sequence described in reference 24. The
production and characterization of this ER-specific antibody have previously
been described (33, 40). After deparaffinization and rehydration, the lung section
was boiled in 10 mM citrate buffer for antigen retrieval. The cooled sections were
incubated in 0.5% H2O2 to quench endogenous peroxidase. To block unspecific
binding of secondary antibodies, sections were incubated in blocking solution
(5% normal goat serum). Primary antibody 503 was added (1:500 dilution in
blocking solution, incubated overnight at 4°C). The ER antibody MC20 (Santa
Cruz Biotechnology) was diluted 1:500, and antibodies against surfactant apo-
protein A (SP-A) and the intracellular proform of surfactant apoprotein C
(proSP-C) (N-19 and M-20, respectively, from Santa Cruz Biotechnology) were
diluted 1:200 in blocking solution. After several washes, the Vectastain ABC kit
(Vector Laboratories, Burlingame, Calif.) was used for visualization. All slices
were slightly counterstained with Mayer’s hematoxylin and mounted. Control
experiments including incubation without primary antibodies, as well as studies
with preadsorbed antibody, were all negative. Sections for immunofluorescence
were deparaffinized and rehydrated. To block unspecific binding of secondary
antibodies, sections were incubated in blocking solution (0.1 M lysine). Primary
antibody against smooth muscle -actin (clone 1A4; Sigma, St. Louis, Mo.) was
used at a 1:500 dilution. For visualization, a secondary fluorescein isothiocya-
nate-conjugated donkey anti-mouse antibody (Jackson ImmunoResearch Labo-
ratories, West Grove, Pa.) was used at a 1:100 dilution. After counterstaining
with 4,6-diamidinio-2-phenylindole (DAPI), slides were mounted and exam-
ined with a Zeiss Axioplan 2 microscope with filters for fluorescein isothiocya-
nate and DAPI.
Protein extraction and Western blot analysis. All tissue handling was done at
4°C. Tissue samples were homogenized for a few seconds with a Polytron PT3100
in a buffer containing 600 mM Tris  HCl, 1 mM EDTA (pH 7.4) and protease
inhibitor mixture tablets (Roche Molecular Biochemicals, Mannheim, Ger-
many), and the homogenates were centrifuged for 1 h at 50,000  g. To load
equal amounts of protein for Western blot analysis, the protein content of the
supernatant fractions was measured by a Bio-Rad (Hercules, Calif.) protein
assay with bovine serum albumin as the standard. For ER detection, samples
were precipitated with trichloroacetic acid (TCA), and the precipitate was
washed with methanol. Samples were placed on dry ice for 30 min, and the
proteins were recovered by centrifugation. Pellets were then dissolved in sodium
dodecyl sulfate (SDS) sample buffer and loaded on the gel. For SP-A and Clara
cell secretory protein (CCSP), equal amounts of protein (20 g) were loaded.
Proteins were resolved on SDS–10, 12, and 15% polyacrylamide gels for ER,
SP-A, and CCSP, respectively. Transfer to polyvinylidene difluoride membranes
was done by electroblotting in Tris-glycine buffer. The membranes were checked
for equal transfer by Ponceau staining. The membranes were blocked in 10%
skimmed milk in phosphate-buffered saline (PBS) buffer–0.1% NP-40. Incuba-
tion with antibodies was done at dilutions of 1:3,000 for ER LBD (33, 40), 1:100
for SP-A (Santa Cruz Biotechnology), and 1:3,000 for CCSP (22) in the same
buffer as used for the blocking reaction. The ER LBD antibody is a rabbit
polyclonal antibody prepared by using the LBD of human ER1 (amino acids
320 to 527). The production and characterization of this ER-specific antibody
are described in references 33 and 40. All incubations were performed overnight
at 4°C. After washing with PBS buffer–0.1% NP-40, horseradish peroxidase-
coupled secondary antibodies (1:10,000; Santa Cruz Biotechnology) were added
for 2 h at room temperature. After washing with PBS buffer–0.1% NP-40, the
signals were visualized by using the enhanced chemiluminescence method (Am-
ersham Pharmacia Biotech, Little Chalfont, United Kingdom).
N-terminal sequencing of proteins. To obtain sufficient ER for N-terminal
amino acid sequencing, cytosol from 10 g of lung was prepared in 50 ml of the
Tris-EDTA buffer described above. This was diluted 10-fold with 20 mM sodium
phosphate buffer, pH 7.4, to reduce the ionic concentration. Heparin-Sepharose
(1 ml) was added, and the mixture was gently rotated for 1 h at 5°C. Heparin-
Sepharose was recovered by centrifugation and washed 5 times with 20 mM
sodium phosphate buffer. Proteins were eluted with 1 M NaCl, precipitated with
10% TCA, washed with methanol, and resolved on SDS gels in 6 lanes. Proteins
were transferred to polyvinylidene difluoride membranes, a strip was cut from
one lane for detection of ER by Western blotting, and the rest of the membrane
was stained with Coomassie brilliant blue. Protein bands corresponding to those
reacting with the LBD antibody were cut from the membrane, and N-terminal
sequencing was performed with an Applied Biosystems 473A protein sequencer.
Sucrose gradient sedimentation. Tissues, frozen in liquid nitrogen, were pul-
verized in a dismembrator (Braun, Kronberg, Germany) in 10 mM Tris-HCl, pH
7.5, 1.5 mM EDTA, and 5 mM sodium molybdate. Cytosol was obtained by
centrifugation of the homogenate at 204,000 g. Cytosols were incubated for 3 h
at 0°C with 10 nM tritiated estradiol in the presence or absence of excess
radio-inert estradiol (50 nM), and the bound and unbound steroids were sepa-
rated with Dextran-coated charcoal. Sucrose density gradients (10 to 30% [wt/
vol] sucrose) were prepared in buffer containing 10 mM Tris-HCl, 1.5 mM
EDTA, 1 mM -monothioglycerol (Sigma), and 10 mM KCl. Samples of 200 l
were layered on 3.5-ml gradients and centrifuged at 4°C for 16 h at 300,000  g.
Successive 100-l fractions were collected from the bottom by paraffin oil dis-
placement, by using a collector of our own design, and assayed for radioactivity
by liquid scintillation counting. For ER detection, samples were precipitated
with TCA, and the precipitate was washed with methanol. Samples were placed
on dry ice for 30 min, and the proteins were recovered by centrifugation. Pellets
were then dissolved in SDS sample buffer and resolved by SDS-polyacrylamide
gel electrophoresis by using 4 to 20% gradient gels.
Electrophoretic mobility shift assay. Estrogen receptor DNA binding was
measured in nuclear extracts from primary mouse Clara cells. Primary Clara cells
were isolated as described by Oreffo et al. (25). From these cells, nuclear proteins
were prepared and electrophoretic mobility shift assays were performed essen-
tially as described by Cassel et al. (6). Briefly, nuclear proteins were incubated
with a labeled duplexed ERE (12) (sequence, 5-GGG TAG AGG TCA CTG
TGA CCT CTC GA-3) in binding buffer (100 mM KCl, 10 mM Tris-HCl [pH
7.5], 2 mM dithiothreitol, 5% glycerol, and 0.9 M estradiol) with or without
anti-estrogen receptor antibodies (503 and LBD, see above) (33, 40). In some
experiments, unlabeled duplexed oligonucleotides were included as competitors:
either the ERE-containing oligonucleotide as described above or an oligonucleo-
tide carrying a single nucleotide substitution in one half site that has been
described to disrupt DNA binding of estrogen receptors (34) (sequence [the
mutated nucleotide is indicated by a lowercase letter], 5-GGG TAG AaG TCA
CTG TGA CCT CTC GA-3).
Transgenic mice. The transgenic mice carrying the luciferase reporter gene
under the transcriptional control of an estrogen response element in front of a
herpes simplex virus thymidine kinase promoter have been described elsewhere
(7). Heterozygous male mice (2 months old) were injected subcutaneously with
50 g of E2/kg of body weight or 250 g of hydroxytamoxifen or vehicle (veg-
etable oil)/kg as control. At the indicated time points, the animals were sacrificed
and luciferase activity was assayed as described.
Morphometry. Sections from lungs fixed by intratracheal inflation at constant
pressure as described above were chosen at random and stained with hematox-
ylin and eosin. From these sections, randomly selected microscopic fields were
photographed at 10 magnification with a Zeiss Axioplan 2 microscope. Five
fields were analyzed per animal. The pictures were enlarged uniformly and used
for morphometric analysis. All alveoli in each field were counted. The number of
cells was determined by counting the number of stained nuclei. All pictures were
counted by two independent observers who were unaware of the genotype of the
animals. Means and standard deviations were calculated, and statistical compar-
isons were performed by unpaired Student’s t test.
Quantitative reverse transcription-PCR. cDNA was synthesized by using the
SuperScript first-strand synthesis system for reverse transcription-PCR (Life
Technologies, Paisley, United Kingdom) according to the instructions of the
manufacturer. For real-time quantitative reverse transcription-PCR analysis,
predeveloped TaqMan assay reagents for mouse GM-CSF mRNA and 18S
rRNA (Applied Biosystems) were used according to the instructions of the
manufacturer. For PDGF-A mRNA, the sequences of the primers used were
5-GGT CCA CCA CCG CAG TGT-3 (upper) and 5-GGA CCT CTT TCA
ATT TTG GCT TC-3 (lower), and they were used together with the SYBR
Green PCR master mix kit (Applied Biosystems) according to the instructions of
the manufacturer. The specificity of the PCR product was ensured by agarose gel
electrophoresis in conjunction with melting curve analysis by using the Dissoci-
ation Curves software (Applied Biosystems) according to the instructions of the
manufacturer. All analyses were carried out on an ABI PRISM 7700 sequence
detector (Applied Biosystems).
Transient transfection studies. A549 cells were routinely cultured in Dulbec-
co’s minimal essential medium (GibcoBRL, Paisley, United Kingdom) supple-
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mented with 10% fetal bovine serum, 1% L-glutamine, 100 U of penicillin/ml,
and 100 g of streptomycin/ml. Twenty-four hours before transfection, cells were
seeded in 12-well plates. Transient transfections were carried out as previously
described (27). Briefly, the Lipofectamine Plus reagent (GibcoBRL) was used in
serum, phenol red, and antibiotic-free media according to the instructions of the
manufacturer. The 1.8-kb PDGF-A promoter-luciferase reporter gene construct
and the 1.6-kb GM-CSF promoter-luciferase reporter gene construct were kind
gifts from David M. Kaetzel (Department of Molecular and Biomedical Phar-
macology, College of Medicine, University of Kentucky, Lexington, Ky.) and
Peter Cockerill (Division of Human Immunology, Hanson Centre For Cancer
Research, Institute for Medical and Veterinary Science, Adelaide, Australia),
respectively. Each well received 200 ng of the reporter plasmid and 5 ng of
pSG5-ER (expressing the mouse ER) (28), or the parental vector, as indi-
cated. Twenty nanograms of cytomegalovirus–-galactosidase plasmid (constitu-
tively expressing -galactosidase) was included as a control for transfection
efficiency. Serum-containing medium with the addition of hormones (10 nM
17-estradiol, 250 nM ICI 182,780) as indicated was added 3 h posttransfection,
and the cells were incubated for 24 h before harvest. Data are presented as
inductions (n-fold) of luciferase activity corrected for the internal standard and
represent the means standard deviations of the results from three independent
experiments performed in duplicate. The activity of the luciferase reporter trans-
fected without estrogen receptor-expressing plasmid and without hormone treat-
ment was arbitrarily set to 1.
RESULTS
ER is the predominant estrogen receptor in the lung. As
outlined in the introduction, previous data indicate that estro-
gens affect lung development, physiology, and carcinogenesis.
However, there is very little information about the mechanisms
of estrogen action and estrogen receptor expression in the
normal lung. The lung has been estimated to consist of 40 or
more different cell types (5). For this reason, we started our
investigations of a potential estrogen action in the lung by
analyzing estrogen receptor expression by immunohistochem-
istry on adult mouse lung sections. As seen in Fig. 1A, upper
panel, extensive nuclear ER staining was observed both in the
bronchiolar epithelium and in the alveolar region. In the bron-
chiolar epithelium, the majority of cells express ER, indicat-
ing the presence of this nuclear receptor in both ciliated cells
and nonciliated secretory Clara cells, the predominant cell
populations in this area of the lung. The pattern of expression
in the alveolar region is compatible with the presence of ER
in both alveolar type II cells and in type I cells. No ER
staining could be detected (Fig. 1A, lower panel; mouse mam-
mary gland inset as positive control). No differences with re-
gard to ER staining were observed when sections from male
and female lungs were compared (data not shown). Western
blotting with lung extracts confirmed the expression of ER
(Fig. 1B, lane 2). In contrast, lung extracts from knockout mice
lacking ER (14) (Fig. 1B, lane 3) exhibited no immunoreac-
tivity, corroborating the specificity of the antibody. N-terminal
sequence analysis of the bands from SDS gels further con-
firmed ER expression and showed that the doublet around 65
kDa corresponds to the two 530- and 549-amino-acid ER
isoforms (10). These data are in agreement with previous anal-
yses of estrogen receptor mRNA in the rat lung by reverse
transcription-PCR (15). They show that ER is highly ex-
pressed in the adult mouse lung and also indicate that ER is
the predominant pulmonary estrogen receptor.
ER present in the lung binds estradiol and DNA in vitro.
To investigate whether lung ER is biologically active, we
investigated its potential to bind its natural ligand 17-estra-
diol, as well its capability to interact with an ERE in vitro.
Sucrose density gradient fractionation of lung extracts showed
specific estradiol binding (at 10 nM) in the 4S region (Fig. 2A).
Western blot analysis revealed ER immunoreactivity in cor-
responding fractions (Fig. 2B). Extracts from Sf9 cells overex-
pressing ER (40) exhibited estradiol binding in the 4S region
as well (Fig. 2A). As expected, in extracts from MCF-7 cells,
ER immunoreactivity and estrogen binding were detected in
an 8S peak. In the lung, no ER immunoreactivity or 8S
estradiol-binding peak was detected (Fig. 2A and data not
shown). DNA binding was analyzed in electrophoretic mobility
shift assays with an oligonucleotide containing a consensus
ERE (12). A shift was observed when incubations were per-
formed with nuclear extracts from isolated murine Clara cells
(Fig. 3A, lane 2). When antibodies directed against the LBD of
ER or the entire protein (503) were included (Fig. 3A, lanes
3 and 4, respectively), the shift was clearly diminished, and in
the case of the LBD antibody, a supershift appeared, together
indicating that the shift contains ER. The specificity of the
shifted complex was demonstrated as these bands were effi-
ciently abolished by competition with unlabeled homologous
oligonucleotide (Fig. 3B, lanes 2 and 3) while no competition
was observed upon inclusion of unlabeled oligonucleotide car-
rying a single nucleotide substitution described to disrupt DNA
binding by estrogen receptors (34) (Fig. 3B, lanes 4 to 5).
These results corroborate the finding that ER is the major
estrogen receptor expressed in the lung and demonstrate that
it is functional with regard to ligand binding and DNA binding
in in vitro assays.
Estrogen receptors in the lung confer estrogen responsive-
ness in vivo. To extend our studies of the biological activity of
ER in the lung, we investigated the estrogen responsiveness
of the lung in vivo. For this purpose, we used transgenic mice
in which a luciferase reporter gene is under the control of an
ERE. The development of these mice and their use in assess-
ing tissue-specific estrogen-mediated transcriptional activity
have been reported previously (7). Male mice were used to
avoid background activation from endogenous estrogen. As
shown in Fig. 4A, a robust stimulation of reporter gene expres-
sion in the lung occurred 6 h after estradiol treatment. Treat-
ment with the antiestrogen tamoxifen blocked estradiol acti-
vation, confirming estrogen receptor-dependence of the
reporter gene activation (Fig. 4B). These results clearly show
the presence of a transcriptionally active estrogen receptor in
the lung. Based on the above data demonstrating the presence
of ER, but not ER, in the lung we conclude that the acti-
vation of the ERE-luciferase reporter gene in the lungs of
these mice is most likely mediated by ER. Together, these in
vitro and in vivo experiments show that the lung contains
functional ER and is estrogen responsive, suggesting ER as
a mediator of estrogen effects in the lung.
Adult female mice lacking ER show altered alveolar struc-
ture. To gain insight into the role of estrogens and ER in the
lung we utilized knockout mice lacking ER (ER/) (14)
and compared the lungs of these mice with lungs from WT
mice. Since gender differences in alveolar structure have been
reported (20), we initially compared the histology of lungs of
ER/ and WT mice. These comparisons revealed clear dif-
ferences in alveolar structure. Lungs from adult female
ER/ mice have larger and fewer alveoli than their WT
littermates (Fig. 5A), and morphometric analyses corroborated
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significant changes in alveolar number (Table 1). No differ-
ences between ER/ and WT lungs were observed in male
mice. To investigate when the difference between ER/ and
WT female lungs appears during development, the histology of
WT and ER/ lungs was compared at embryonic day 19,
postnatal day 14, and 4 weeks and 3 months of age. No differ-
ences in lung morphology were observed at the embryonic
stage or in mice of 14 days or 4 weeks of age. However, in the
FIG. 1. ER is highly expressed in the lung. (A) Immunohisto-
chemistry for ER in mouse lung. Lungs obtained from WT and
ER/ mice were fixed by intratracheal inflation, sectioned, and
stained with antibodies for ER (upper panel) and ER (lower panel).
Counterstaining was done with hematoxylin. Alveolar type I (arrow-
head) and type II (open arrow) cells as well as bronchiolar epithelial
cells (filled arrow) are indicated in the upper panel. The inset in the
lower panel is a section of mouse mammary gland used as a positive
control for ER immunostaining. (B) Western blot analysis for ER in
mouse lung extracts. Lane 1, recombinant ER short form, included as
a positive control; lanes 2 to 4, lung extracts from ER/, ER/,
and ER/ mice. (C) N-terminal sequencing of ER immunoreactive
bands. The upper line represents the result of N-terminal sequencing
of the area corresponding to the 65-kDa doublet shown in panel B.
The lower line is the amino acid sequence of mouse ER.
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3-month-old mice, altered alveolar structure was evident (Ta-
ble 1). This indicates that the phenotype in female lungs de-
velops after sexual maturation. The morphometric analysis
also demonstrated that the ratio between cell number and
alveolar number is not changed in ER/ lungs, suggesting
that the differences in alveolar structure are more related to
structural alterations than to changes in cellular proliferation.
No morphological changes were observed in the conducting
airways. From the morphometric analysis, it was also evident
that the adult female lung has a larger number of alveoli than
that of the male (Table 1). This gender difference in alveolar
structure is in accordance with the previous observations by
Massaro et al. (20). In addition, our morphometric analysis
revealed that, with regard to alveolar number, the female
ER/ lung is strikingly similar to the male lung (Table 1).
Thus, we conclude that the gender differences in alveolar num-
ber and size, evident in sexually mature animals, do not occur
in the ER/ mice.
Alveolar formation is dependent on specialized mesenchy-
mal cells in the walls of the alveolar sacs (18). In the mouse
lung parenchyma, smooth muscle -actin is a specific marker
for these cells. To investigate whether these specialized mes-
enchymal cells were affected in ER/ mice, we stained WT
and ER/ lungs for smooth muscle -actin. The staining
pattern for these cells was changed in accordance with the
altered alveolar structure. In the WT lung, stained cells were
more evenly distributed compared to the staining pattern in
the ER/ lung (Fig. 5B), indicating that the positioning of
these cells is affected in lungs from ER/ mice. This suggests
that a deficiency in alveolar formation underlies the differences
in alveolar number. Together, these results indicate that the
lack of ER renders the female lung unresponsive to estrogen
during sexual maturation and thus the normal increase in al-
veolar number does not occur in the lungs of female ER/
mice.
Surfactant accumulation in mice lacking ERb. Histological
examination of lungs from 1-year-old mice revealed amor-
phous, acellular, lightly eosinophilic material present inside the
alveolar spaces of the female ER/ mice (Fig. 6A). This
material stained positive for SP-A, one of the major surfactant
proteins (17) (Fig. 6B), indicating accumulation of surfactant
components. As a marker for the surfactant-producing alveolar
type II cells, an antibody specific for proSP-C (17) was used to
stain serial sections. However, no differences were noted in the
number, or staining intensity, of the type II cells (Fig. 6B).
Also, the proSP-C specific antibody failed to stain the accu-
mulated material. The reactivity of the accumulated material
with the antibody against SP-A, together with the absence of
reactivity for the intracellular proSP-C, suggests that the ma-
terial represents extracellular accumulation of surfactant in-
side the alveolar spaces. Accumulation was observed in four of
five 1-year-old female ER/ mice investigated. In contrast,
no evidence of surfactant accumulation was observed in 1-year-
old WT female or male mice or in ER/ male mice (five
animals examined per group). As demonstrated above, ER is
expressed at high levels in both bronchiolar and alveolar epi-
thelial cells in the lung. Thus, we also analyzed a marker for
bronchiolar epithelial cells, the CCSP (37), to investigate
whether loss of ER affected bronchiolar epithelial cell func-
tion as well. However, no differences in the levels or patterns of
expression were observed (data not shown). These results sug-
gest that alveolar homeostasis is affected in female lungs lack-
ing ER, resulting in accumulation of surfactant components.
PDGF-A and GM-CSF are reduced in the lungs of mice
lacking ER. Lungs of female ER/ mice thus exhibit al-
terations in alveolar number and surfactant homeostasis.
PDGF-A and GM-CSF are two signaling molecules central for
these aspects of lung homeostasis. PDGF-A is a major regu-
lator of alveolar formation. Mice with a targeted disruption of
the PDGF-A gene show a marked decrease in the number of
alveoli because of defects in alveolar formation as a conse-
quence of deficiencies in the specialized interstitial cells form-
ing the alveolar walls (cells that express smooth muscle -ac-
tin) (4, 18). GM-CSF, on the other hand, is critical in the
regulation of lung surfactant. Disruption of the gene for GM-
CSF in mice results in severe abnormalities in alveolar ho-
FIG. 2. ER in the lung binds ligand. (A) Sucrose density gradient
assay for 17-estradiol binding. Extracts from mouse lung (LUNG),
mouse lung incubated with an excess of unlabeled estradiol
(LUNGE2), Sf9 cells overexpressing ER (ERbeta), and MCF-7
cells (MCF-7) were fractionated on sucrose density gradients and
assayed for binding of tritiated estradiol. (B) Western blot analysis for
ER in fractions from sucrose gradient sedimentation of mouse lung
extracts. Fractions analyzed by Western blotting are indicated. Recom-
binant ER short form (58 kDa) was included as a positive control in
the first lane (ER).
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meostasis with gross accumulation of surfactant (9, 38). We
therefore compared the expression of these two signaling mol-
ecules in the lungs of WT and ER/ female mice. For this
purpose, PDGF-A and GM-CSF expression were analyzed by
quantitative real-time reverse transcription-PCR. The results
in Table 2 show that both PDGF-A and GM-CSF mRNAs
were significantly lower in lungs from female ER/ mice
than in WT littermates. In male mice, no differences were
detected between WT and ER/ mice. PDGF-A mRNA
levels in male mice were similar to the levels in ER/ female
mice, in accordance with the similarity in alveolar number
between the male and female ER/ mouse lungs. With
regard to GM-CSF expression, male lungs instead exhibited
mRNA levels similar to those of female WT lungs, in agree-
ment with the absence of surfactant accumulation in the male
WT and ER/ lungs. In light of the central role of these
factors in regulation of alveolar structure and surfactant ho-
meostasis, these results suggest that the phenotypic alterations
observed in female ER/ mice may be related to diminished
PDGF-A and GM-CSF signaling in the lungs.
Transcriptional regulation of PDGF-A and GM-CSF by es-
trogen in lung epithelial cells. The decreased levels of
PDGF-A and GM-CSF in ER/ lungs suggest estrogen and
ER as important regulators of these factors in the lung. Es-
trogen-dependent stimulation of both factors has been dem-
onstrated in reproductive organs (11, 32); the nature of this
regulation has, however, not been investigated. In the lung,
estrogen may directly regulate the expression of these factors,
since both are expressed in the bronchiolar and alveolar epi-
thelial cells (3, 31), the same cells that express ER, enabling
direct transcriptional activation by ER. The effects of estro-
gen on the PDGF-A and GM-CSF promoters were, therefore,
examined in transient transfection experiments. For this pur-
pose, the ER-negative lung epithelial cell line A549 was
transfected with a reporter gene driven by a 1.8-kb PDGF-A
promoter fragment or a 1.6-kb GM-CSF promoter fragment.
When an ER expression plasmid was cotransfected in these
cells, expression of the reporter driven by the PDGF-A pro-
moter fragment increased up to sixfold (Fig. 7A) and the
GM-CSF promoter was stimulated up to ninefold by estradiol
(Fig. 7B). Neither promoter was stimulated by estradiol when
ER expression plasmid was omitted. The ER-dependent
response to estradiol was, in both cases, blocked by addition of
the pure antiestrogen ICI 182,780. These data demonstrate an
ER-dependent estrogen responsiveness of the PDGF-A and
GM-CSF promoters in lung epithelial cells and indicate that
response elements reside within 1.8 and 1.6 kb, respectively,
from the start sites of transcription. A computer search for
consensus EREs (12) revealed 9 of 13 and 10 of 13 matches in
these parts of the PDGF-A and GM-CSF promoters, respec-
FIG. 3. ER in the lung binds DNA. (A) Electrophoretic mobility shift assay with ER antibodies. Extracts from isolated lung epithelial cells
were analyzed by using a consensus ERE (12) as a probe. The arrow indicates the position of the retarded complex, and “Free” indicates the
position of free unbound probe. Antibody (Ab.) directed against the LBD was included in lane 3 and caused the appearance of a supershift
(arrowhead) and the disappearance of the retarded complex. Inclusion of the 503 antibody also clearly diminished the retarded complex (lane 4).
Addition of the respective antibodies to the probe alone did not affect the migration of the probe (lanes 5 and 6). (B) Competition (Comp.) with
unlabeled homologous and mutated oligonucleotides. To establish specific binding, increasing concentrations of unlabeled homologous oligonu-
cleotide (ERE) were added in 50- to 100-fold excesses (lanes 2 and 3) or unlabeled mutated oligonucleotide carrying a single nucleotide
substitution in one half-site that has been described to disrupt DNA binding by estrogen receptors (mutERE) (34) was added in a 50- to 100-fold
excess (lanes 4 and 5). , present; , absent; N.E., nuclear extract.
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tively. This indicates that estrogens may directly influence the
transcription of these genes in the lung. PDGF-A and GM-
CSF are key regulators of alveolar formation and surfactant
homeostasis, respectively. Thus, these results, taken together,
suggest that the phenotypic alterations observed in female
ER/ mice may be related to a lack of proper estrogen
regulation of these genes by ER. This provides a possible
mechanism behind the observed lung phenotype in ER/
mice.
DISCUSSION
This study shows, in vivo and in vitro, that ER is the
functional estrogen receptor in the lung; it is abundantly ex-
pressed in the lung epithelium and biologically active. Lungs of
adult female mice with a targeted disruption of the ER gene
exhibit decreased numbers of alveoli as a result of deficient
alveolar formation after sexual maturation. In addition, female
ER/ mice exhibit evidence of surfactant accumulation.
PDGF-A and GM-CSF, key regulators of alveolar formation
and surfactant homeostasis, respectively, are decreased in
lungs of adult female ER/ mice and were found to be
transcriptionally regulated by ER. Together, this provides a
possible mechanism behind the observed lung phenotype in
ER/ mice. The data presented here suggest that ER has
a role in the alveolar formation occurring in the sexually ma-
ture female and indicate ER as an important factor in post-
natal lung development and homeostasis.
Alveolar formation (or alveologenesis) occurs postnatally by
the formation of alveolar septa. Formation of these septa is
dependent on a specialized subset of mesenchymal cells that
also deposit elastin, the molecule providing elasticity to the
lung (18, 30). Adult virgin female rats and mice have a larger
number of alveoli, smaller in size, than males. These differ-
ences probably exist to meet the metabolic demands of repro-
duction (20). They are first seen after the animals have reached
sexual maturity and seem to be mediated mainly by estrogens
(19). Our morphometric analysis shows that this increase in
alveolar number does not occur in the female ER/ mice. It
seems likely that the absence of ER renders the lung unre-
sponsive to the elevated circulating estrogen levels in the sex-
ually mature female. In males, no differences in alveolar struc-
ture were detected between WT and ER/ mice. An
explanation for this sexual dimorphism is that at sexual matu-
rity females have higher levels of circulating estrogens than
males. Furthermore, aromatase, the enzyme converting andro-
gen to estrogen, is lacking in the male mouse lung (36), making
it unlikely that there would be any substantial local production
of estrogens in the male lung. In addition, recently presented
results from the mice carrying the ERE-luciferase reporter
gene reveal that whereas transcriptional activation can occur
independent of hormone in some organs, this does not occur in
the lung (8). Together, this supports the notion that the pres-
ence of circulating estrogens acting via ER in the sexually
mature female is the major determinant of the observed lung
phenotype.
The extracellular signaling molecule PDGF-A is a key reg-
ulator of alveologenesis, as demonstrated in mice carrying a
targeted disruption of the PDGF-A gene. PDGF-A/ mice
exhibit complete failure of alveolar septation and loss of elastin
expression and die postnatally due to pulmonary problems (4).
Further analysis of these mice suggests that PDGF-A from the
lung epithelium is crucial for the proliferation, migration, and
elastin deposition of the mesenchymal cells central for alve-
ologenesis. In the absence of PDGF-A, these mesenchymal
cells do not take their correct positions and fail to deposit
elastin, resulting in failure of alveolar formation (18). In light
of these observations, our findings of reduced PDGF-A expres-
sion and changed positioning of the mesenchymal cells in the
ER/ female lung, together with transcriptional regulation
of the PDGF-A promoter via ER in lung epithelial cells,
provide a mechanistic explanation for the decreased number of
alveoli in ER/ female mice. That the lung phenotype of
female ER/ mice is less severe than that of PDGF-A/ is
to be expected, as estrogens have their main role in alveolar
development after sexual maturation and serve to induce the
increase in alveolar number observed at this time. This is in
line with the study by Massaro et al. (20), in which estrogen is
proposed to cause the increase in alveolar number in female
rodents after sexual maturity. Our results provide a potential
FIG. 4. Estrogen receptors in the lung confer estrogen responsive-
ness in vivo. The effects of estrogen on luciferase reporter gene activity
in lungs from ERE-luc transgenic mice are shown. Male transgenic
mice carrying the luciferase reporter gene under the control of an
estrogen response element were injected with vehicle (Cont) or 17-
estradiol (E2), and lung luciferase activity was assayed at different time
points (A) or with estradiol or estradiol plus hydroxytamoxifen (Tam)
at 6 h (B). Bars represent averages  standard deviations of 4 to 10
individual animals assayed in duplicates. , P	 0.01 by Student’s t test;
RLU, luminescence units per milligram of protein.
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mechanism for this effect, and we speculate that estrogens act
via ER in lung epithelial cells to directly modify PDGF-A
expression and thereby influence alveologenesis (Fig. 8). In
conclusion, our data suggest that, in the absence of ER,
estrogen-dependent up-regulation of PDGF-A will not occur
and, therefore, mesenchymal cells will not be stimulated to
form additional alveoli, resulting in the loss of the estrogen-
dependent increase in alveolar number occurring in the sexu-
ally mature female.
When mice lacking GM-CSF were generated, an unantici-
pated role of GM-CSF signaling in surfactant homeostasis was
uncovered. These mice exhibited severe abnormalities in the
alveolar region of the lung with accumulation of surfactant and
increased levels of surfactant proteins (9, 38). Further studies
FIG. 5. Structural changes in lungs from mice lacking ER.
(A) Histology of lungs from WT and ER/ female mice. Lungs
obtained from WT and ER/ mice were fixed by intratracheal in-
flation at constant pressure, sectioned, and stained with hematoxylin-
eosin. Microscopic fields were selected at random and photographed at
different magnifications. (B) Immunostaining for smooth muscle -ac-
tin in WT and ER/ mouse lungs. Lungs obtained from WT and
ER/ female mice were fixed and stained with antibody for smooth
muscle -actin. After nuclear counterstaining with DAPI, sections
were examined with a fluorescence microscope.
TABLE 1. Morphometric analysis of WT and ER/
mouse lungsa
Mouse description No. of alveoli/field No. of nuclei/no. of alveoli
Female, 4 wk
WT 338  19 2.66  0.04
ER/ 317  56 (NS) 2.69  0.10 (NS)
Female, 3 mo
WT 433  86 2.70  0.26
ER/ 309  44* 2.75  0.36 (NS)
Male, 3 mo
WT 306  27 2.71  0.36
ER/ 301  16 (NS) 2.67  0.18 (NS)
a Data are means  standard deviations (n 
 4). *, P 	 0.05; NS, not
significant (unpaired Student’s t test).
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of GM-CSF signaling in surfactant homeostasis suggest that
GM-CSF, locally produced by the lung epithelium and acting
mainly on alveolar macrophages, is essential for normal sur-
factant clearance (31). In 1-year-old female ER/ mice, we
found evidence of surfactant accumulation in the alveolar
spaces. These findings prompted us to investigate GM-CSF
signaling in female ER/ mice, revealing decreased GM-
CSF expression. On the basis of these results, together with the
transfection studies demonstrating that estrogens can regulate
the GM-CSF promoter via ER, we speculate that estrogens
FIG. 6. Surfactant accumulation in mice lacking ER. (A) Histology of lungs from 1-year-old WT and ER/ female mice. Lungs obtained
from WT and ER/ mice were fixed by immersion, sectioned, and stained with hematoxylin-eosin. (B) Immunostaining for SP-A and proSP-C
in 1-year-old WT and ER/ female mouse lungs. Lungs obtained from WT and ER/ female mice were fixed, and serial sections were stained
with antibodies for SP-A and proSP-C. Counterstaining was done with hematoxylin.
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act via ER in lung epithelial cells to directly modify GM-CSF
expression and thereby influence surfactant homeostasis (Fig.
8). Again, the phenotype of ER/ mice is less severe than
that of GM-CSF/ mice, probably because the levels of GM-
CSF in ER/ lungs are reduced and not completely abol-
ished.
Taken together, our results provide new mechanistic insights
regarding estrogen action in the lung. We have formulated a
speculative model shown in Fig. 8, where we propose that
estrogen acts through ER in the lung epithelium and influ-
ences the transcription of PDGF-A and GM-CSF. This can
give further insight into the effects of estrogen on lung carci-
nogenesis, since PDGF-A is highly mitogenic for a large num-
ber of different cell types in vitro (3) and GM-CSF has been
suggested to stimulate proliferation of alveolar type II cells in
in vivo mouse models (31). Our data thus provide new infor-
mation that could help in understanding the gender differences
in lung cancer. In the human population, women are more
susceptible than males to the deleterious effects of tobacco
smoking, are more prone to develop chronic obstructive pul-
monary disease, and incur a higher risk of lung cancer (29, 41).
There also appears to be a sexual dimorphism regarding types
of lung cancer (13, 35). The reasons for these differences are
unknown, but estrogens are likely to play a major role, since in
animal models, there are estrogen-dependent sex differences in
susceptibility towards tobacco-associated lung carcinogens
(23). Furthermore, epidemiological studies suggest that hor-
mone replacement therapy with estrogen is associated with a
higher risk of lung cancer in postmenopausal women (1, 39). In
the present study, we show that estrogen directly regulates the
PDGF-A and GM-CSF promoters via ER in lung cells. Our
demonstration of direct estrogen regulation of these potent
growth factors in the lungs provides new vistas for the inves-
tigation of the mechanisms underlying the observed gender
differences in lung cancer.
In conclusion, the data presented in this paper give new
mechanistic insights regarding estrogen action in the lung, as
summarized in Fig. 8, including an understanding of the ob-
served gender differences in postnatal lung development and
structure. This provides a basis for further studies aimed at
understanding the sex differences in common and severe lung
disorders such as chronic obstructive pulmonary disease and
FIG. 7. Transcriptional regulation of PDGF-A and GM-CSF by ER in transient transfections of lung epithelial cells. The lung epithelial cell
line A549 was transfected with a luciferase reporter gene under the control of a 1.8-kb fragment of the PDGF-A promoter (A) or with the same
reporter under the control of a 1.6-kb fragment of the GM-CSF promoter (B). Both promoters were tested in the absence () or presence ()
of ER expression plasmid. Cells were treated with 17-estradiol (E2) or E2 and the pure antiestrogen ICI 182,780 (ICI). RLU, luciferase
luminescence units per -galactosidase units.
FIG. 8. Proposed model for mechanisms of estrogen signaling in
the lung epithelium. The observed phenotypic consequences from the
disruption of estrogen signaling in ER/ lungs are indicated by
bracketed arrows.
TABLE 2. Levels of PDGF-A and GM-CSF mRNA in WT and
ER/ mouse lungsa
Mouse description PDGF-A GM-CSF
Female
WT 2.89  0.75 1.36  0.20
ER/ 1.23  0.95* 0.90  0.07**
Male
WT 1.17  0.46 1.56  0.23
ER/ 1.25  0.62 (NS) 1.30  0.50 (NS)
a Data are means standard deviations (n
 3 to 4). *, P	 0.05; ** , P	 0.01;
NS, not significant (unpaired Student’s t test).
VOL. 23, 2003 ER IN THE LUNG 8551
lung cancer. Perhaps increased knowledge in this field may also
help uncover new possibilities for treatment of these diseases.
ACKNOWLEDGMENTS
This work was supported by grants from the Swedish Research
Council (grant no. 14677 and 14678), the Swedish Cancer Society, the
A˚ke Wiberg Research Foundation, the Swedish Society for Medical
Research, and KaroBio AB.
We thank Peter Cockerill and David M. Kaetzel for reagents needed
for this study. We are grateful for the skilled technical assistance
provided by Lena Nordlund-Mo¨ller and Christina Thulin and for the
very valuable suggestions and help from Gil-Jin Shim, Shigehira Saji,
Zhang Weihua, Sari Ma¨kela¨, and Tove Berg.
REFERENCES
1. Adami, H. O., I. Persson, R. Hoover, C. Schairer, and L. Bergkvist. 1989.
Risk of cancer in women receiving hormone replacement therapy. Int. J.
Cancer 44:833–839.
2. Ballard, P. L. 1989. Hormonal regulation of pulmonary surfactant. Endocr.
Rev. 10:165–181.
3. Betsholtz, C., and E. W. Raines. 1997. Platelet-derived growth factor: a key
regulator of connective tissue cells in embryogenesis and pathogenesis. Kid-
ney Int. 51:1361–1369.
4. Bostrom, H., K. Willetts, M. Pekny, P. Leveen, P. Lindahl, H. Hedstrand, M.
Pekna, M. Hellstrom, S. Gebre-Medhin, M. Schalling, M. Nilsson, S. Kur-
land, J. Tornell, J. K. Heath, and C. Betsholtz. 1996. PDGF-A signaling is a
critical event in lung alveolar myofibroblast development and alveogenesis.
Cell 85:863–873.
5. Breeze, R. G., and E. B. Wheeldon. 1977. The cells of the pulmonary airways.
Am. Rev. Respir. Dis. 116:705–777.
6. Cassel, T. N., L. Norlund-Mo¨ller, O. Andersson, J.-A˚. Gustafsson, and M.
Nord. 2000. C/EBPalpha and C/EBPdelta activate the Clara cell secretory
protein gene through interaction with two adjacent C/EBP-bindng sites.
Am. J. Respir. Cell Mol. Biol. 22:469–480.
7. Ciana, P., G. Di Luccio, S. Belcredito, G. Pollio, E. Vegeto, L. Tatangelo, C.
Tiveron, and A. Maggi. 2001. Engineering of a mouse for the in vivo profiling
of estrogen receptor activity. Mol. Endocrinol. 15:1104–1113.
8. Ciana, P., M. Raviscioni, P. Mussi, E. Vegeto, I. Que, M. G. Parker, C.
Lowik, and A. Maggi. 2003. In vivo imaging of transcriptionally active estro-
gen receptors. Nat. Med. 9:82–86.
9. Dranoff, G., A. D. Crawford, M. Sadelain, B. Ream, A. Rashid, R. T. Bron-
son, G. R. Dickersin, C. J. Bachurski, E. L. Mark, J. A. Whitsett, and R. C.
Mulliugan. 1994. Involvement of granulocyte-macrophage colony-stimulat-
ing factor in pulmonary homeostasis. Science 264:713–716.
10. Fuqua, S. A., R. Schiff, I. Parra, W. E. Friedrichs, J. L. Su, D. D. McKee, K.
Slentz-Kesler, L. B. Moore, T. M. Willson, and J. T. Moore. 1999. Expression
of wild-type estrogen receptor beta and variant isoforms in human breast
cancer. Cancer Res. 59:5425–5428.
11. Gray, K., B. Eitzman, K. Raszmann, T. Steed, A. Geboff, J. McLachlan, and
M. Bidwell. 1995. Coordinate regulation by diethylstilbestrol of the platelet-
derived growth factor-A (PDGF-A) and -B chains and the PDGF receptor
alpha- and beta-subunits in the mouse uterus and vagina: potential mediators
of estrogen action. Endocrinology 136:2325–2340.
12. Klein-Hitpass, L., G. U. Ryffel, E. Heitlinger, and A. C. Cato. 1988. A 13 bp
palindrome is a functional estrogen responsive element and interacts specif-
ically with estrogen receptor. Nucleic Acids Res. 16:647–663.
13. Kmietowicz, Z. 1998. Women at double risk of small cell lung cancer. BMJ
317:1614.
14. Krege, J. H., J. B. Hodgin, J. F. Couse, E. Enmark, M. Warner, J. F. Mahler,
M. Sar, K. S. Korach, J. A. Gustafsson, and O. Smithies. 1998. Generation
and reproductive phenotypes of mice lacking estrogen receptor beta. Proc.
Natl. Acad. Sci. USA 95:15677–15682.
15. Kuiper, G. G., B. Carlsson, K. Grandien, E. Enmark, J. Haggblad, S. Nils-
son, and J. A. Gustafsson. 1997. Comparison of the ligand binding specificity
and transcript tissue distribution of estrogen receptors alpha and beta. En-
docrinology 138:863–870.
16. Kuiper, G. G. J. M., E. Enmark, M. Pelto-Huikko, S. Nilsson, and J.-A˚.
Gustafsson. 1996. Cloning of a novel estrogen receptor expressed in rat
prostate and ovary. Proc. Natl. Acad. Sci. USA 93:5925–5930.
17. Kuroki, Y., and D. R. Voelker. 1994. Pulmonary surfactant proteins. J. Biol.
Chem. 269:25943–25946.
18. Lindahl, P., L. Karlsson, M. Hellstrom, S. Gebre-Medhin, K. Willetts, J. K.
Heath, and C. Betsholtz. 1997. Alveogenesis failure in PDGF-A-deficient
mice is coupled to lack of distal spreading of alveolar smooth muscle cell
progenitors during lung development. Development 124:3943–3953.
19. Massaro, G. D., J. P. Mortola, and D. Massaro. 1996. Estrogen modulates
the dimensions of the lung’s gas-exchange surface area and alveoli in female
rats. Am. J. Physiol. 270:L110–L114.
20. Massaro, G. D., J. P. Mortola, and D. Massaro. 1995. Sexual dimorphism in
the architecture of the lung’s gas-exchange region. Proc. Natl. Acad. Sci.
USA 92:1105–1107.
21. Mendelson, C. R., P. C. MacDonald, and J. M. Johnston. 1980. Estrogen
binding in human fetal lung tissue cytosol. Endocrinology 106:368–374.
22. Nord, M., M. La˚g, T. N. Cassel, M. Randmark, R. Becher, H. J. Barnes, P. E.
Schwarze, J.-A˚. Gustafsson, and J. Lund. 1998. Regulation of CCSP (PCB-
BP/Uteroglobin) expression in primary cultures of lung cells - involvement of
C/EBP. DNA Cell Biol. 17:481–492.
23. Noronha, R. F., and C. M. Goodall. 1984. The effects of estrogen on single
dose dimethylnitrosamine carcinogenesis in male inbred Crl/CDF rats. Car-
cinogenesis 5:1003–1007.
24. Ogawa, S., S. Inoue, T. Watanabe, A. Orimo, T. Hosoi, Y. Ouchi, and M.
Muramatsu. 1998. Molecular cloning and characterization of human estro-
gen receptor betacx: a potential inhibitor of estrogen action in human.
Nucleic Acids Res. 26:3505–3512.
25. Oreffo, V. I., A. Morgan, and R. J. Richards. 1990. Isolation of Clara cells
from the mouse lung. Environ. Health Perspect. 85:51–64.
26. Patrone, C., S. Andersson, L. Korhonen, and D. Lindholm. 1999. Estrogen
receptor-dependent regulation of sensory neuron survival in developing dor-
sal root ganglion. Proc. Natl. Acad. Sci. USA 96:10905–10910.
27. Pettersson, K., F. Delaunay, and J. A. Gustafsson. 2000. Estrogen receptor
beta acts as a dominant regulator of estrogen signaling. Oncogene 19:4970–
4978.
28. Pettersson, K., K. Grandien, G. G. Kuiper, and J. A. Gustafsson. 1997.
Mouse estrogen receptor beta forms estrogen response element-binding
heterodimers with estrogen receptor alpha. Mol. Endocrinol. 11:1486–1496.
29. Prescott, E., A. M. Bjerg, P. K. Andersen, P. Lange, and J. Vestbo. 1997.
Gender difference in smoking effects on lung function and risk of hospital-
ization for COPD: results from a Danish longitudinal population study. Eur.
Respir. J. 10:822–827.
30. Prodhan, P., and T. B. Kinane. 2002. Developmental paradigms in terminal
lung development. Bioessays 24:1052–1059.
31. Reed, J. A., and J. A. Whitsett. 1998. Granulocyte-macrophage colony-stim-
ulating factor and pulmonary surfactant homeostasis. Proc. Assoc. Am. Phy-
sicians 110:321–332.
32. Robertson, S. A., G. Mayrhofer, and R. F. Seamark. 1996. Ovarian steroid
hormones regulate granulocyte-macrophage colony-stimulating factor syn-
thesis by uterine epithelial cells in the mouse. Biol. Reprod. 54:183–196.
33. Saji, S., E. V. Jensen, S. Nilsson, T. Rylander, M. Warner, and J. A. Gustafs-
son. 2000. Estrogen receptors alpha and beta in the rodent mammary gland.
Proc. Natl. Acad. Sci. USA 97:337–342.
34. Schwabe, J. W., L. Chapman, J. T. Finch, and D. Rhodes. 1993. The crystal
structure of the estrogen receptor DNA-binding domain bound to DNA:
how receptors discriminate between their response elements. Cell 75:567–
578.
35. Sekine, I., Y. Nishiwaki, T. Yokose, K. Nagai, K. Suzuki, and T. Kodama.
1999. Young lung cancer patients in Japan: different characteristics between
the sexes. Ann. Thorac. Surg. 67:1451–1455.
36. Simpson, E. R., Y. Zhao, V. R. Agarwal, M. D. Michael, S. E. Bulun, M. M.
Hinshelwood, S. Graham-Lorence, T. Sun, C. R. Fisher, K. Qin, and C. R.
Mendelson. 1997. Aromatase expression in health and disease. Recent Prog.
Horm. Res. 52:185–213.
37. Singh, G., and S. L. Katyal. 2000. Clara cell proteins. Ann. N. Y. Acad. Sci.
923:43–58.
38. Stanley, E., G. J. Lieschke, D. Grail, D. Metcalf, G. Hodgson, J. A. Gall,
D. W. Maher, J. Cebon, V. Sinickas, and A. R. Dunn. 1994. Granulocyte/
macrophage colony-stimulating factor-deficient mice show no major pertur-
bation of hematopoiesis but develop a characteristic pulmonary pathology.
Proc. Natl. Acad. Sci. USA 91:5592–5596.
39. Taioli, E., and E. L. Wynder. 1994. Re: Endocrine factors and adenocarci-
noma of the lung in women. J. Natl. Cancer Inst. 86:869–870.
40. Weihua, Z., S. Makela, L. C. Andersson, S. Salmi, S. Saji, J. I. Webster, E. V.
Jensen, S. Nilsson, M. Warner, and J. A. Gustafsson. 2001. A role for
estrogen receptor beta in the regulation of growth of the ventral prostate.
Proc. Natl. Acad. Sci. USA 98:6330–6335.
41. Zang, E. A., and E. L. Wynder. 1996. Differences in lung cancer risk between
men and women: examination of the evidence. J. Natl. Cancer Inst. 88:183–
192.
8552 PATRONE ET AL. MOL. CELL. BIOL.
